Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection

Marrelli, Daniele; Roviello, Franco; Stefano, Alfonso De; Fotia, G; Giliberto, Camillo; Garosi, Lorenzo; Pinto, Enrico

doi:10.1016/j.jamcollsurg.2003.08.013

Cited by 61 publications

(40 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The metastatic rate to above four sites were much higher than previous literature reports, which were 13.5% for liver metastasis,15 0.5%‐0.96% for lung metastasis,16, 17, 18 0.9%‐3.8% for bone metastasis19, 20, 21, 22 and 0.16%‐0.69% for brain metastasis 23, 24. The actual frequency of metastasis to bone and brain originating from GC was underestimated because usually bone and brain imaging was not performed as a routine evaluation and asymptomatic metastasis might be overlooked 25, 26.…”

Section: Discussioncontrasting

confidence: 64%

See 1 more Smart Citation

Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER‐based study

et al. 2018

View full text Add to dashboard Cite

The hematogenous metastatic pattern of gastric cancer (GC) was not fully explored. Here we analyzed the frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from GC patients. Data queried for this analysis included GC patients from the Surveillance, Epidemiology, and End Results Program database from 2010 to 2014. All of statistical analyses were performed using the Intercooled Stata 13.0 (Stata Corporation, College Station, TX). All statistical tests were two‐sided. Totally, there were 19 022 eligible patients for analysis. At the time of diagnosis, there were 7792 patients at stage IV, including 3218 (41.30%) patients with liver metastasis, 1126 (14.45%) with lung metastasis, 966 (12.40%) with bone metastasis and 151 (1.94%) with brain metastasis. GC patients with lung or liver metastasis have a higher risk of bone and brain metastasis than those without lung nor liver metastasis. Intestinal subtype had significantly higher rate of liver and lung metastasis, while diffuse type was more likely to have bone metastasis. Proximal stomach had significantly higher risk to develop metastasis than distal stomach. African‐Americans had the highest risk of liver metastasis and Caucasian had the highest prone to develop lung and brain metastasis. The median survival for patients with liver, lung, bone, and brain metastasis was 4 months, 3 months, 4 months and 3 months, respectively. It is important to evaluate the status of bone and brain metastasis in GC patients with lung or liver metastasis. Knowledge of metastatic patterns is helpful for clinicians to design personalized pretreatment imaging evaluation for GC patients.

show abstract

Section: Discussioncontrasting

confidence: 64%

“…The major feature of recurrence in GC patients is intraabdominal spread 13. Liver is the most common site of hematogenous metastasis of GC 14, 15. Lung metastasis is reported to be around 0.5%‐0.96% in GC patients 16, 17, 18.…”

Section: Introductionmentioning

confidence: 99%

Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER‐based study

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Liver metastasis is an important prognostic factor, accounting for 10 -15% of gastric cancer recurrences after curative resection (Marrelli et al, 2004). This is a noncurable, fatal disease with a 5-year survival of less than 10% (Sakamoto et al, 2003).…”

mentioning

confidence: 99%

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis

et al. 2006

View full text Add to dashboard Cite

Gastric cancer metastasised to the liver was found to overexpress HER2 at a significantly higher incidence than primary gastric cancers. The purpose of the present study was to investigate the possibility of molecular therapy targeting HER2 overexpression in gastric cancer liver metastasis. We developed three new HER2-overexpressing gastric cancer cell lines (GLM-1, GLM-2, GLM-4) without epidermal growth factor receptor (EGFR) mutations derived from such liver metastasis, two of which had HER2 gene amplifications. All these GLM series of cell lines were highly sensitive to gefitinib in vitro, a specific inhibitor of EGFR tyrosine kinase (Iressa) rather than anti-HER2 antibody trastuzumab (Herceptin), whereas most of the HER2 low-expressing counterparts were not. In these HER2-overexpressing GLM series, protein kinase B (Akt), but not extracellular signal-regulated kinase 1/2 (ERK1/2), was constitutively phosphorylated, and gefitinib efficiently inhibited this Akt phosphorylation, induced strong apoptosis in vitro and exhibited antitumour activity in tumour xenografts in nude mice. This gefitinib-mediated antitumour effect in xenograft was significantly potentiated by trastuzumab treatment. On the other hand, gefitinib-resistant cells (GLM-1R) exhibited increased EGFR expression, followed by constitutive activation of mitogen-activated protein kinase (MAPK) pathway. These results suggest that the antitumour effect of gefitinib is due to the effective inhibition of HER2-driven constitutive activation of phosphatidylinositol-3-kinase (PI3K)/Akt pathway, and that the acquired resistance to gefitinib is due to the constitutive activation of Ras/MAPK pathway in compensation for PI3K/Akt pathway. Gastric cancer liver metastasis with HER2 overexpression would be a potential molecular target for gefitinib and trastuzumab.

show abstract

“…TMs have been used for the early screening, diagnosis, evaluating prognosis, monitoring curative effect, and detecting relapse in patients of cancer (Bates et al, 1991;Zhang et al, 2009). However, each TM has its limitation in terms of diagnostic value, especially for the early diagnosis (Marrelli et al, 2004;Patriti et al, 2007). It is therefore necessary to find new molecules and combination of several of these TMs at the same time (Wang et al, 2005;Gupta et al, 2007;Park et al, 2007;.…”

Section: Discussionmentioning

confidence: 99%

Tumor Markers for Diagnosis, Monitoring of Recurrence and Prognosis in Patients with Upper Gastrointestinal Tract Cancer

Jing

Wang²,

Xu³

et al. 2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Risk factors for liver metastases after curative surgical procedures for gastric cancer: a prospective study of 208 patients treated with surgical resection

Cited by 61 publications

References 32 publications

Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER‐based study

Frequency and clinicopathological features of metastasis to liver, lung, bone, and brain from gastric cancer: A SEER‐based study

Molecular basis for sensitivity and acquired resistance to gefitinib in HER2-overexpressing human gastric cancer cell lines derived from liver metastasis

Tumor Markers for Diagnosis, Monitoring of Recurrence and Prognosis in Patients with Upper Gastrointestinal Tract Cancer

Contact Info

Product

Resources

About